CAS 1246030-96-5

GSK-2250665A

CAS : 1246030-96-5

GSK-2250665A

Degré de pureté : ≥95%

Ref: 54-BUP22537

GSK 2250665A

Produit contrôlé

CAS : 1246030-96-5

Formule : C₂₆H₂₉N₅OS

Couleur et forme : Neat

Masse moléculaire : 459.606

Ref: TR-G797605

GSK 2250665A

CAS : 1246030-96-5

GSK 2250665A is an antiviral agent, which is a product of GlaxoSmithKline's research and development. It operates as a hepatitis C virus (HCV) NS3/4A protease inhibitor. The NS3/4A protease is essential for viral replication, and by inhibiting this enzyme, GSK 2250665A effectively disrupts the viral life cycle. This mode of action specifically targets the HCV replication machinery, decreasing the viral load in patients. The use of GSK 2250665A is primarily in the treatment of chronic hepatitis C, often in combination with other antiviral medications to enhance therapeutic efficacy. Through its targeted inhibition, it contributes to viral clearance and the management of hepatitis C, a disease which, if untreated, can lead to severe liver damage and other complications.

Formule : C₂₆H₂₉N₅OS

Degré de pureté : Min. 95%

Masse moléculaire : 459.61 g/mol

Ref: 3D-WZB03096

GSK-2250665A

CAS : 1246030-96-5

GSK-2250665A is an (Itk) inhibitor (pKi 9.2) with selectivity over Aurora B and Btk, inhibiting IFNγ in PBMCs for T-cell signaling studies.

Formule : C₂₆H₂₉N₅OS

Degré de pureté : 99.38%

Couleur et forme : Solid

Masse moléculaire : 459.61

Ref: TM-T27458